This phase III trial is looking at the safety and effectiveness of giving an immunotherapy (Durvalumab) in combination with chemotherapy (Gemcitabine and Cisplatin) in patients with muscle-invasive bladder cancer.
This trial is treating patients with muscle-invasive bladder cancer.
This is a systemic therapy trial.
You may be able to join this trial if:
- You have been diagnosed with cancer, but have not received any treatment.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
- You have had certain treatments, surgical procedures or drugs.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Use the hyperlinks, where available to access additional clinical trial information.
A Phase III, Randomized, Open-Label, Multi-Center, Global Study to Determine the Efficacy and Safety of Durvalumab in Combination With Gemcitabine+Cisplatin for Neoadjuvant Treatment Followed by Durvalumab Alone for Adjuvant Treatment in Patients With Muscle-Invasive Bladder Cancer
Patients in this trial will be randomly assigned to receive chemotherapy plus Durvalumab as neoadjuvant treatment, or chemotherapy alone.
Recruiting Hospitals Read More